Physician profile
George Postic
NPI 1447231469
$3,949.91
in general payments reported to CMS, 2019-2025
26 companies · $644 in 2025
The $644 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $249 · 2021: $864 · 2022: $653 · 2023: $604 · 2024: $628 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,875.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,371.10 | 2019-2025 | |
| Pfizer INC. | $585.29 | 2019-2025 | |
| Celgene Corporation | $364.55 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $268.23 | 2020-2024 | |
| Nestle Healthcare Nutrition INC. | $200.37 | 2020-2021 | |
| Janssen Biotech, INC. | $191.86 | 2019-2025 | Tremfya |
| Qol Medical, LLC | $151.05 | 2022-2025 | Sucraid |
| Genzyme Corporation | $146.60 | 2023-2025 | |
| Fresenius Kabi USA, LLC | $121.20 | 2024 | Idacio |
| Takeda Pharmaceuticals U.S.A., INC. | $83.50 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $76.73 | 2021-2022 | |
| Echosens North America, INC. | $53.83 | 2019 | |
| Daiichi Sankyo INC. | $43.71 | 2024-2025 | Injectafer |
| Amgen INC. | $38.38 | 2023 | Avsola, Amjevita |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.06 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $32.62 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $32.58 | 2023 | Dificid |
| Regeneron Healthcare Solutions, INC. | $23.77 | 2024 | Dupixent |
| Medtronic, INC. | $22.68 | 2025 | Interstim |
| Ipsen Biopharmaceuticals, INC | $20.49 | 2025 | Iqirvo |
| Tetraphase Pharmaceuticals, INC. | $18.67 | 2019 | |
| Pharmacosmos Therapeutics INC. | $14.45 | 2021 | |
| Ferring Pharmaceuticals INC. | $14.03 | 2025 | Rebyota |
| W. L. Gore & Associates, INC. | $12.86 | 2021 | |
| Intercept Pharmaceuticals, INC. | $12.83 | 2021 | |
| Alfasigma USA, INC. | $11.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Postic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.